Aniracetam
Cognitive · Racetam
Tier C+
Bottom line
Read Off Label grades Aniracetam as C+ (5.7/10) based on weak evidence, variable benefit magnitude, and a low-risk safety profile.
Short plasma half-life (~1-2.
Studied, labeled, or reported-use context: 750-1500 mg/day PO with fat, divided doses — Rx in some EU countries; research chem in US; not individualized guidance.
What the evidence says
Short plasma half-life (~1-2.5 hr) but active metabolites (N-anisoyl-GABA) may persist. Anecdotal reports of reduced anxiety and improved verbal fluency. Much less studied than piracetam in rigorous modern trials.
Mechanism
Positive allosteric modulator of AMPA receptors (slows desensitization); also cholinergic and serotonergic/dopaminergic modulation; fat-soluble unlike piracetam
Studied, labeled, or reported dose & route
750-1500 mg/day PO with fat, divided doses
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Aniracetam's effects?
- Read Off Label rates the evidence for Aniracetam as Weak and the benefit magnitude as variable, producing an overall grade of C+ (5.7/10). Short plasma half-life (~1-2.
- What safety findings are reported for Aniracetam?
- Aniracetam has a low risk profile in the database. Low (reported) Legal status: Rx in some EU countries; research chem in US.
- What doses or routes are reported for Aniracetam?
- 750-1500 mg/day PO with fat, divided doses This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Aniracetam work?
- Positive allosteric modulator of AMPA receptors (slows desensitization); also cholinergic and serotonergic/dopaminergic modulation; fat-soluble unlike piracetam
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.